Company Filing History:
Years Active: 2019-2022
Title: Jae-Sung Yi: Innovator in Tyrosine Kinase Inhibitors
Introduction
Jae-Sung Yi is a notable inventor based in Hamden, CT (US). He has made significant contributions to the field of biochemistry, particularly in the development of compositions and methods for using tyrosine kinase inhibitors. His work has implications for treating various cardiovascular diseases and conditions associated with RASopathies.
Latest Patents
Jae-Sung Yi holds 2 patents. His latest patents focus on compositions and methods of inhibiting tyrosine phosphorylation. One aspect of his invention includes a composition comprising a low-dosage tyrosine kinase inhibitor that effectively decreases tyrosine phosphorylation. Additionally, he describes methods for treating cardiovascular diseases or conditions associated with RASopathies that involve aberrant protein tyrosine phosphorylation. His work also addresses congenital heart disease associated with Noonan syndrome and aims to decrease aberrant levels of Protein Zero-Related (PZR) tyrosyl phosphorylation.
Career Highlights
Jae-Sung Yi is affiliated with Yale University, where he continues to advance research in his field. His innovative approaches have garnered attention and recognition within the scientific community.
Collaborations
He collaborates with Anton Bennett, contributing to the advancement of research in tyrosine kinase inhibitors and their applications in medicine.
Conclusion
Jae-Sung Yi's work in the field of tyrosine kinase inhibitors represents a significant advancement in medical research, with the potential to improve treatment options for various cardiovascular conditions. His contributions are invaluable to the ongoing exploration of innovative therapeutic methods.